Favorable outcome of allogeneic hematopoietic stem cell transplantation for relapsed or refractory acute promyelocytic leukemia in childhood

Bone Marrow Transplantation

Volumn 34, Issue 9, 2004, Pages 795-798

  Bourquin, J P ^a,b   Thornley, I ^a,b   Neuberg, D ^a   Brennan, L ^a   Kung, A ^a,b   Clark, J ^a,b   Lehmann, L ^a,b   Guinan, Eva C ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Acute promyelocytic leukemia; Allogeneic hematopoietic stem cell transplantation; Pediatric; Relapse

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; CYTOKINE; ETOPOSIDE; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; RETINOIC ACID; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE DISEASE; ADOLESCENT; ADULT; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CHRONIC DISEASE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DONOR; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX; HLA MATCHING; HUMAN; HUMAN CELL; INCIDENCE; MALE; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL TIME; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HUMANS; INCIDENCE; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; RECURRENCE; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 7944222521     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704676     Document Type: Article

References (18)

1. Raimondi SC, Chang MN, Ravindranath Y et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood 1999; 94: 3707-3716.
2. Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol 1998; 101 130-140.
3. Woods WG, Neudorf S, Gold S et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001; 97: 56-62.
4. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
5. Fenaux P, Chastang C, Chevret S et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999; 94: 1192-1200.
6. Sanz MA, Martin G, Gonzalez M et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004; 103: 1237-1243.
7. Meloni G, Diverio D, Vignetti M et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene. Blood 1997; 90: 1321-1325.
8. Sanz M, Arcese W, De la Rubia J et al. Stem cell transplantation (SCT) for acute promyelocytic leukaemia in the ATRA era: a survey of the European Blood and Marrow Transplantation Group (EBMT). Blood 2000; 96 (Suppl. 1): 522a.
9. Thomas X, Dombret H, Cordonnier C et al. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Leukemia 2000; 14: 1006-1013.
10. Soignet SL, Frankel SR, Douer D et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852-3860.
11. 3) in the treatment of patients with acute promyelocytic leukemia: the M.D. Anderson experience. Cancer 2003; 97: 2218-2224.
12. Lo-Coco F, Romano A, Mengarelli A et al. Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease. Leukemia 2003; 17: 1930-1933.
13. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735.
14. Chao NJ, Schmidt GM, Niland JC et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993; 329: 1225-1230.
15. Meyers JD, Reed EC, Shepp DH et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988; 318: 70-75.
16. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
17. Rowlings PA, Przepiorka D, Klein JP et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997; 97: 855-864.
18. Lansky SB, List MA, Lansky LL et al. The measurement of performance in childhood cancer patients. Cancer 1987; 60: 1651-1656.